Small molecules which reverse Vemurafenib treatment
Canned Analysis
FAIR Metrics
0 evaluations
General Information
AccessionDCA00011931
TitleSmall molecules which reverse Vemurafenib treatment
DescriptionThe L1000 database was queried in order to identify small molecule perturbations which reverse the gene expression signature induced by Vemurafenib treatment in the Primary leukemic cells (purified from peripheral blood) - 72 Hours cell type.
Analysis URLhttp://amp.pharm.mssm.edu/L1000CDS2/#/result/58d1db2ae467bea600fb918a
Upload DateSeptember 20, 2017
Uploadermaayanlab
Metadata
Analysis Curatorcadimo
CREEDS IDdrug:2509
Cell TypePrimary leukemic cells (purified from peripheral blood) - 72 Hours
Drug NameVemurafenib
DrugBank IDDB08881
Organismhuman
SMILES IDCCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c1c[nH]c2c1cc(cn2)c1ccc(cc1)Cl)F
L1000CDS2 parameters
Directionreverse
Characteristic Direction parameters
Control SamplesGSM1557455, GSM1557462, GSM1557466, GSM1557470, GSM1557474
Perturbed SamplesGSM1557456, GSM1557457, GSM1557463, GSM1557467, GSM1557471, GSM1557475
Tools used in the analysis
Dataset Accession
Characteristic Direction
Published March 2014
A geometrical multivariate approach to identify differentially expressed genes
26829
L1000CDS2
Published August 2016
An ultra-fast LINCS L1000 Characteristic Direction signature search engine
7756
Datasets used in the analysis
Keyword
Tool Name
GSE63790
Gene Expression Omnibus
Braf inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia, and exert anti-leukemic activity
14
FAIR Evaluation
Sorry, you must be signed in to evaluate this object.